SS-31 peptide and mitochondrial disease: what the Phase 3 data actually showed

What did @hackiechan1 actually say?

The creator's core argument is that SS-31's failed Phase 3 trial shouldn't be taken as a final verdict on the peptide. They claim SS-31 "targets your mitochondria" to improve energy efficiency and reduce oxidative stress, but that the main clinical trial tested it in people with primary mitochondrial myopathy, a population so severely affected that the compound may not have had a fair shot. They also describe a "12 day protocol" where users feel debilitating fatigue around days two to three, which they interpret as "deep repair at the cellular level," followed by improved energy they attribute to better ATP output.

They also point to the MMPOWER and RENEWAL studies as newer, more relevant evidence, and close by soliciting anecdotes from the comments as supporting data. That last part is worth flagging immediately: anecdotes are not clinical evidence, and framing them as "real world results" worth paying attention to alongside peer-reviewed studies is a category error.

Does the science back this up?

Partially, and it depends heavily on which claim you're looking at. The mechanistic claims are reasonably grounded. SS-31, also called elamipretide, does bind to cardiolipin on the inner mitochondrial membrane. That part is well-established in the literature.

The trial failure is real. The SPIBA trial (Karaa et al., 2018, JAMA Neurology) was a randomized controlled trial in primary mitochondrial myopathy patients and did not meet its primary endpoint. The creator is also correct that cardiolipin abnormalities are documented in mitochondrial myopathy (Claypool and Koehler, 2012, Nature Reviews Molecular Cell Biology), which is a legitimate scientific reason to question whether a cardiolipin-targeting drug would work as well in that population.

The MMPOWER-3 trial (2020) also failed to meet its primary endpoint in the same population, which the creator does not mention. The RENEWAL study examined heart failure with preserved ejection fraction, a different condition entirely. Citing these as general evidence that SS-31 "works" in healthy-ish people doing optimization protocols is a significant leap from what those trials actually tested.

What did they get wrong (or right)?

Credit where it's due: the creator correctly identifies that trial populations matter. Testing a compound in people with severe mitochondrial disease and generalizing the failure to everyone is genuinely bad science reasoning. That's a real methodological point, and researchers have made similar arguments in the literature (Parikh et al., 2017, Neurology).

But there are real problems here. First, the "12 day protocol" with days two to three of "debilitating fatigue" being reframed as cellular repair is speculative at best. There is no clinical evidence that this fatigue pattern reflects mitochondrial repair in humans. It could equally reflect inflammatory response, hormetic stress, or simply a bad reaction. Presenting it as likely evidence of benefit is misleading without citing any data.

Second, the creator says cardiolipin in affected patients "might already be abnormal." That's actually well-documented, not speculative, but the way it's framed makes it sound like a hypothesis when it's closer to established science.

Third, there is no rigorous human trial showing SS-31 improves energy or reduces oxidative stress in generally healthy adults. Claiming it "might actually be a different story" for healthy users is not supported by evidence. It may be true. We don't know. That distinction matters.

What should you actually know?

SS-31 is a genuinely interesting research compound with a plausible mechanism and a real track record of preclinical promise. The problem is that "interesting mechanism" and "failed trials" is not a combination that supports confident claims about optimization use in healthy people.

The SPIBA and MMPOWER-3 failures are not minor setbacks. They were well-designed randomized controlled trials. The creator's argument that the population was too sick is a reasonable scientific hypothesis, but it has not been tested in a healthy or mildly affected population in a controlled way. Anecdotes and the RENEWAL trial data (which focused on cardiac function, not general energy) do not fill that gap.

If you're considering SS-31 for energy optimization or general wellness, understand that you would be using a compound with no clinical evidence of benefit in a population like yours, unclear dosing parameters, and a side effect profile that includes the kind of debilitating fatigue the creator describes without a verified explanation for why that happens. That's not automatically a reason to avoid it. But it is a reason to be skeptical of confident framing around a 12-day protocol as though the mechanism is understood.

• SS-31 has not been approved by the FDA for any indication.
• Compounded versions of SS-31 are not equivalent to the pharmaceutical-grade elamipretide used in trials.
• No clinical trial has tested SS-31 in healthy adults for energy or recovery optimization.